A. Mislowsky

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

P. Whitworth, P. Beitsch, F. D. de Snoo, 2016, Annals of Surgical Oncology.

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

P. Whitworth, P. Beitsch, Danielle Boselli, 2015, Annals of Surgical Oncology.

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

P. Whitworth, P. Beitsch, J. Pellicane, 2017, Annals of Surgical Oncology.

Breast Cancer Surgery Trend Changes Since the Introduction of BRCA1/2 Mutation Screening: A Retrospective Cohort Analysis of 158 Mutation Carriers Treated at a Single Institution

S. Sonnad, S. Domchek, J. Tchou, 2011, Annals of Surgical Oncology.

Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy

W. Audeh, P. Whitworth, P. Beitsch, 2022, JCO precision oncology.

Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.

W. Audeh, P. Whitworth, P. Beitsch, 2022, Surgical oncology.

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

P. Whitworth, P. Beitsch, J. Pellicane, 2014, Annals of Surgical Oncology.

A scarless technique of umbilical hernia repair in the adult population

D. V. Nasrallah, A. Mislowsky, A. Hemphill, 2008, Hernia.